{'fraction_non_alphanumeric': 0.019328585961342827, 'fraction_numerical': 0.01017293997965412, 'mean_word_length': 5.074074074074074, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Therapy of hepatitis B virus carriers].

Examination of 200 gastroenterological patients with a suspected chronic diffuse liver disease has demonstrated that only in 18.9% of the patients with chronic hepatitis, the disease was induced by the virus. Based on the experience gained with the treatment of 7 patients with chronic hepatitis B it is concluded that sanitation may be performed with levamisole. However, the data obtained in the course of the 5-year observation over sanitation of HBsAg carriers (25 subjects) do not provide any convincing evidence in favour of levamisole sanitation. The authors hold that at the blood transfusion stations the prophylaxis of serum hepatitis falls short of ideal. Selection of the donors according to CCIE does not give any guarantee against the viral hepatitis B carrier state. Like patients with viral hepatitis B, the HBsAg carriers badly need active prophylactic-and-treatment medical examination with the use of the antiviral agents.